Variability of risk factors and diabetes complications

Ceriello, Antonio; Prattichizzo, Francesco

doi:10.1186/s12933-021-01289-4

Cited by 83 publications

(47 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies measured SUA only once in the general population. Nonetheless, there is a potential association between T2D, CVD and long-term variability of SUA ( 32 ). For this reason, we investigated the relationship between the uric acid variability and CVD in patients with T2D.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes

Kim

Lee

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Cardiovascular disease (CVD) is associated with morbidity and mortality in patients with type 2 diabetes mellitus (T2D). However, the role of serum uric acid as a risk factor for developing cardiovascular disease is controversial. This study investigated whether uric acid variability was associated with new-onset symptomatic CVD in patients with T2D, requiring percutaneous coronary intervention.Methods: A total of 1,071 patients were enrolled in this retrospective cross-sectional study after propensity score matching. Patients with T2D and new-onset symptomatic CVD who received percutaneous coronary intervention for the first time, and with at least three consecutive 6-monthly measurements of serum uric acid were recruited from Severance Hospital between January 2015 and December 2019. Uric acid variability was measured by average successive variability (ASV) and analyzed to evaluate a possible correlation with the risk of developing CVD.Results: The patients were divided into quartiles based on the uric acid variability. Patients in the highest quartile were older and presented lower renal function and a higher mortality from CVD. There was a linear association between a high uric acid variability and the development of CVD. Compared to the lowest quartile, patients in the higher quartiles had a higher risk of CVD [quartile 3: adjusted odds ratio (aOR) = 1.76; 95% confidence interval (CI), 1.20–2.82; P = 0.019; quartile 4 aOR = 2.89; 95% CI, 1.74–4.80; P < 0.001].Conclusion: High uric acid variability is independently associated with an increased risk of new-onset symptomatic CVD requiring percutaneous coronary intervention in patients with T2D. Thus, maintaining serum uric acid in a narrow range by prescribing effective medications is essential to prevent new-onset CVD in patients with T2D. Nonetheless, the potential use of uric acid variability as a predictive marker of CVD in patients with T2D needs further validation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…No studies have assessed the correlation between uric acid variability and CVD in patients with T2D ( 32 ). A previous study explored the association between uric acid variability as measured by SD of Z-scores, and coronary heart disease and all-cause mortality in a male population without diabetes ( 51 ).…”

Section: Discussionmentioning

confidence: 99%

Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes

Kim

Lee

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…the square root of the variance, of the body weight measures available during the three years preceding the longitudinal phase of the study. Standard deviation was chosen since it is the most used metric to assess the variability of risk factors [ 11 ]. A minimum of five measures was considered, in order to have a robust estimate of variability.…”

Section: Methodsmentioning

confidence: 99%

Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register

Ceriello

Lucisano

Prattichizzo

et al. 2021

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

Background There is a high incidence of cardiovascular disease in diabetes. Weight variability has been reported as independent risk factor for cardiovascular disease in the general population and preliminarily also in people with type 2 diabetes. Methods Using data from the Swedish National Diabetes Register the possible link between visit-to-visit body weight variability and the risk of cardiovascular complications among people with type 2 diabetes and without prevalent cardiovascular diseases at baseline has been evaluated. Overall, 100,576 people with type 2 diabetes, with at least five measurements of body weight taken over three consecutive years, were included. Variability was expressed as quartiles of the standard deviation of the measures during the three years. The primary composite outcome included non-fatal myocardial infarction, non-fatal stroke, and all-cause mortality and was assessed during five years following the first 3 years of exposure to weight variability. Results After adjusting for known cardiovascular risk factors, the risk of the primary composite outcome significantly increased with increasing body weight variability [upper quartile HR = 1.45; 95% confidence interval 1.39–1.52]. Furthermore, elevated body weight variability was associated with almost all the other cardiovascular complications considered (non-fatal myocardial infarction, non-fatal stroke, all-cause mortality, peripheral arterial disease, peripheral vascular angioplasty, hospitalization for heart failure, foot ulcer, and all-cause mortality). Conclusions High body weight variability predicts the development of cardiovascular complications in type 2 diabetes. These data suggest that any strategy to reduce the body weight in these subjects should be aimed at maintaining the reduction in the long-term, avoiding oscillations.

show abstract

“…T2D is a chronic inflammatory disease, characterized by obesity-associated insulin resistance [16][17][18][19][20]. Autoimmunity plays a pivotal part in a series of chronic diseases [21][22][23].…”

Section: Galectin-3 In Type Diabetesmentioning

confidence: 99%

Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot

Tian

Zhang

et al. 2022

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Galectin-3 is a member of the galectin family, widely expressed in immune cells and plays a role mainly in inflammation, autoimmunity, apoptosis, and chemotaxis. We summarized the roles of Galectin-3 in diabetes and its complications, as well as the underlying mechanisms. Clinical research has determined that the circulating level of Galectin-3 is closely related to diabetes and its complications, thus it is promising to use Galectin-3 as a predictor and biomarker for those diseases. Galectin-3 also may be considered as an ideal therapeutic target, which has broad prospects in the prevention and treatment of diabetes and its complications, especially macrovascular and microvascular complications.

show abstract

Variability of risk factors and diabetes complications

Cited by 83 publications

References 60 publications

Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes

Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes

Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register

Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot

Contact Info

Product

Resources

About